John Magee - Flexion Therapeutics Vice President - Sales

President

Mr. John Magee serves as Vice President Sales of the Company since 2016.
Tenure 8 years
Professional MarksMBA
Phone781 305-7777
Webwww.flexiontherapeutics.com
Magee has more than 35 years of experience as a sales professional and brings extensive experience in successfully recruiting and managing pharmaceutical sales organizations. Prior to joining Flexion, he was head of U.S. sales for the rare disease unit of Shire Pharmaceuticals, where he also served as U.S. sales director for its renal business. During his time in the rare disease unit of Shire, he helped to achieve revenue growth of more than $1 billion. Previously, he held senior sales positions at Esprit Pharma and Bayer Corporationrationrationration. He has a Bachelor’s degree in biology and anthropology from Hamilton College, and completed MBA courses at the Rochester Institute of Technology.

Flexion Therapeutics Management Efficiency

The company has return on total asset (ROA) of (18.99) % which means that it has lost $18.99 on every $100 spent on assets. This is way below average. Flexion Therapeutics' management efficiency ratios could be used to measure how well Flexion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 228.9 M in liabilities. Flexion Therapeutics has a current ratio of 4.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Flexion Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Flexion Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Flexion Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Flexion to invest in growth at high rates of return. When we think about Flexion Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Mario WijkerTeleflex Incorporated
52
Marco MolinariHNI Corp
55
Amy AblesAlphatec Holdings
N/A
Jeffrey LorengerHNI Corp
58
Julie AbramowskiHNI Corp
48
Mark OjedaAlphatec Holdings
N/A
Mark NasonSkechers USA
62
Michael GreenbergSkechers USA
61
James FergusonTeleflex Incorporated
N/A
James LeydenTeleflex Incorporated
52
Matthew McGoughHNI Corp
N/A
Roger GrahamTeleflex Incorporated
N/A
Phillip PaccioneSkechers USA
55
Philip PaccioneSkechers USA
62
Jeffrey BlackAlphatec Holdings
48
Andrew LukowiakTalis Biomedical Corp
52
Karen BoylanTeleflex Incorporated
47
Jason HagedornHNI Corp
50
Jon AllenAlphatec Holdings
N/A
Donna MeadeHNI Corp
55
David SponselAlphatec Holdings
45
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Flexion Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 257 people. Flexion Therapeutics (FLXN) is traded on NASDAQ Exchange in USA and employs 257 people.

Management Performance

Flexion Therapeutics Leadership Team

Elected by the shareholders, the Flexion Therapeutics' board of directors comprises two types of representatives: Flexion Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Flexion. The board's role is to monitor Flexion Therapeutics' management team and ensure that shareholders' interests are well served. Flexion Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Flexion Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Arkowitz, CFO, Principal Financial Officer and Principal Accounting Officer
Sandesh Mahatme, Director
Scott Canute, Director
Mark Levine, Senior Vice President General Counsel, Secretary
Kerry Wentworth, Chief Regulatory Officer
Dan Thornton, Vice President - Market Access
John Magee, Vice President - Sales
Neil Bodick, Chief Medical Officer & Co-Founder
Mark Fraga, Vice President - Marketing
Michael Clayman, CEO, Co-Founder, Board Member
Ann Merrifield, Director
Alan Milinazzo, Independent Director
Jon Mahlowitz, VP of Legal Affairs
Frederick Driscoll, CFO and Principal Accounting Officer
Heath Lukatch, Independent Director
Christina Willwerth, Chief Strategy Officer
Patrick Mahaffy, Chairman of the Board
Samuel Colella, Independent Director
Yamo Deniz, Chief Medical Officer
Mark Stejbach, Director
Scott Kelley, Vice President - Medical Affairs

Flexion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Flexion Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Flexion Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Flexion Therapeutics' short interest history, or implied volatility extrapolated from Flexion Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Consideration for investing in Flexion Stock

If you are still planning to invest in Flexion Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flexion Therapeutics' history and understand the potential risks before investing.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Content Syndication
Quickly integrate customizable finance content to your own investment portal